Oxaliplatin-based chemotherapy in the treatment of elderly patients with metastatic colorectal cancer (CRC)

Massimiliano Berretta, Ernesto Zanet, Guglielmo Nasti, Arben Lleshi, Sergio Frustaci, Francesco Fiorica, Alessandra Bearz, Renato Talamini, Chiara Lestuzzi, Renzo Lazzarini, Rossella Fisichella, Renato Cannizzaro, Rosario Vincenzo Iaffaioli, Salvatore Berretta, Umberto Tirelli

Research output: Contribution to journalArticlepeer-review


Elderly patients constitute a subpopulation with special clinical features that differ from those of the general population and are under-represented in clinical trials. We retrospectively analyzed the toxicity and efficacy of oxaliplatin-based chemotherapy in the treatment of elderly patients affected by metastatic (m) CRC. Seventy-five consecutive patients aged 65-75 years (median age 71 years), 51 males and 24 females, with mCRC and measurable disease, were analyzed. The primary site of metastases was the liver (38.6% of patients). The majority of patients had a performance status (PS) according to the Eastern Cooperative Oncology Group (ECOG) PS before treatment of 0-1 (96%). The overall response rate was 57.3%, median progression-free survival was 7 months and median overall survival was 27 months. The main hematological and extra-hematological toxicities (grade 3 or 4) were neutropenia (20.0%), and neurological toxicity or diarrhea (6.7%), respectively. No toxic death occurred. Oxaliplatin-based chemotherapy maintains its efficacy, and safety in elderly patients with mCRC and good PS. This regimen should be considered in the treatment of this particular setting of patients.

Original languageEnglish
Pages (from-to)271-275
Number of pages5
JournalArchives of Gerontology and Geriatrics
Issue number2
Publication statusPublished - Sept 2012


  • Cancer therapy in elderly
  • Colorectal cancer
  • Metastatic cancer
  • Oxaliplatin

ASJC Scopus subject areas

  • Ageing
  • Geriatrics and Gerontology
  • Health(social science)
  • Gerontology


Dive into the research topics of 'Oxaliplatin-based chemotherapy in the treatment of elderly patients with metastatic colorectal cancer (CRC)'. Together they form a unique fingerprint.

Cite this